Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.
September 06, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience and maintained a $14 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a $14 price target by a reputable analyst suggests a positive outlook for Skye Bioscience. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100